Jorge Daniel Oldan MD, Presenter: Nothing to Disclose

Salvador Borges-Neto MD, Abstract Co-Author: Speakers Bureau, General Electric Company

Michael Morse MD, Abstract Co-Author: Advanced Liquid Logic, Inc. American Physician Institute American Society for Clinical Investigation Amgen, Inc. Archimedes Bayer Bristol-Myers Squibb Defined Health Etubics Corporation Genentech, Inc (Roche Holding) Georgia Society of Clinical Oncology Gerson Lehrman Group, Inc. Health Advances MarketLab dba Focus Pointe Global National Institutes of Health Novartis Onyx PPD, Inc. Pfizer Inc. PhytoChem Pharmaceuticals, Inc. Prometheus Laboratories Inc. Roche Sanofi-Aventis Schlesinger Associates Watermark West Virginia University roda marketing

Jiang Zhu MD, Abstract Co-Author: Nothing to Disclose

The purpose of this study is to determine whether I-131 MIBG has any benefit for survival of patients with pheochromocytoma, paraganglioma, and carcinoid.

We retrospectively reviewed 128 patients with paraganglioma/pheochromocytoma and 215 patients with carcinoid treated with I-131 MIBG over the 24 years of practice at Duke University Hospital with I-131 MIBG therapy. We reviewed medical records, the National Death Registry, and publicly available death records to determine whether patients showed any increase in survival over historical data on patients with carcinoid and pheochromocytoma/paraganglioma, both from treatment and from the date of diagnosis with metastatic disease. 

Using NDI data, and assuming any patient not shown as being dead in the NDI, medical record, or publicly available death records to be alive at least until December 31, 2011 (the last date for which NDI death data was available), median survival times for carcinoid were 1720 days (58 months) from diagnosis of metastatic disease and 877 (29 months) days from treatment. Comparable survival data for metastatic carcinoid after Yao (2008) is 33 months. Median survival times for pheochromocytoma/paraganglioma were 2110 days (70 months) from diagnosis of metastatic disease and 1513 days (50 months) from treatment. This is slightly improved over the average 50% five-year survival rate for metastatic pheochromocytoma and paraganglioma. 

Patients treated with MIBG have higher survival times than average, particularly for carcinoid, suggesting some therapeutic benefit in terms of prolonging survival.

Some prolongation of survival is likely with I-131 MIBG.

Oldan, J, Borges-Neto, S, Morse, M, Zhu, J, Survival of Pheochromocytoma, Paraganglioma, and Carcinoid Patients Treated with I-131 MIBG.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14009456.html